Checklist · Intellectual Property

Building a Patent License Term Sheet: A Practical Checklist

Type
Checklist
Jurisdiction
National
Date
2024-09-03
Topic
Intellectual Property

A patent is a right to exclude and nothing more; a license is how that right becomes revenue, and the term sheet is the architectural drawing every later clause is built from. This checklist takes a patent owner and counsel from the threshold question of whether to license at all, through building a defensible valuation range, to the anatomy of the grant, the royalty architecture, and the protective machinery that keeps the money flowing. It maps the silent doctrinal landmines that void royalty streams a licensor thought were airtight: the Brulotte/Kimble bar on post-expiration royalties, the Lear right of a licensee to attack the very patent it pays to use, the exhaustion rule that ends control at the first authorized sale, and the misuse doctrine that can make a patent unenforceable against the world. It flags the special rules for university and federally funded patents under Bayh-Dole and for standard-essential patents under FRAND. Use it to convert the right to exclude into a durable income stream without giving away the crown jewels. Educational only; not legal advice.

Building a Patent License Term Sheet: A Practical Checklist

Intellectual Property > Patent Licensing | Published 3 September 2024 - Updated 14 January 2025 | UpLaw - uplaw.us

A patent gives its owner no customer, no factory, and no revenue: it grants only the right to stop other people. Licensing is the machine that converts that negative right into positive cash flow, and the term sheet is the machine's blueprint. This checklist builds that blueprint clause by clause, then pressure-tests it against the Supreme Court doctrines that quietly make royalty streams uncollectible.

Keywords: patent license term sheet, royalty architecture, exclusive vs. non-exclusive grant, field of use, apportionment, Georgia-Pacific, Brulotte and Kimble, Lear v. Adkins, patent exhaustion, patent misuse, Bayh-Dole, FRAND, sublicensing, minimum royalties, audit rights, indemnification.

What a term sheet actually is, and why it governs everything downstream

A patent license term sheet is a short document, usually two to five pages, that fixes the economic and legal architecture of a deal before anyone spends real money on a fifty-page definitive agreement. It is to a license what a set of framing drawings is to a building: it decides where the load-bearing walls go, and every later clause either follows those lines or fights them. Get the term sheet right and the definitive agreement is mostly translation. Get it wrong and you spend the drafting phase renegotiating the deal you thought you already had.

Most term sheets are deliberately non-binding as to the deal itself but binding as to a handful of collateral promises. The grant, the royalty, and the protective terms are typically stated "subject to a definitive agreement," so neither side is locked into a transaction that diligence later kills. But three provisions almost always bind on signature: confidentiality (each side has just seen the other's numbers), exclusivity of negotiation for a stated window (so the licensee does not shop your terms), and governing law for the term sheet itself. Say which parts bind and which do not, in one sentence, on the first page. Courts enforce clear "agreements to agree" boundaries and refuse to rescue sloppy ones; a term sheet that is silent on its own legal effect is an invitation to a lawsuit about whether you have a contract at all.

This checklist is organized as eight phases, moving from the threshold "should we license" question through valuation, the grant, the money, the protective machinery, the doctrinal traps, the special-licensor overlays, and the mechanics of closing. Each phase pairs a working checklist with the analysis a licensor needs to fill it in intelligently. For the full arc from valuation psychology through negotiation, read it alongside Monetizing a Patent Through Licensing: From Valuation to Term Sheet, and situate the whole transaction inside The IP Transactions Toolkit.

A running hypothetical will keep the abstractions honest. Imagine MarineFlow, Inc., a six-person company holding U.S. Patent No. 9,XXX,XXX on a corrosion-resistant valve seat for saltwater pumps. MarineFlow has no factory and no sales force. Poseidon Pumps, LLC, a large industrial manufacturer, wants to build the valve into its marine product line. MarineFlow wants revenue without surrendering the invention. Everything below is the anatomy of the term sheet that gets them there. (MarineFlow, Poseidon, and their patent are invented for illustration.)

Phase 1 — Threshold assessment: is this patent worth licensing at all?

Before valuation, before drafting, ask whether the asset can carry a deal. A patent that reads narrowly, is easily designed around, or is about to expire will not command real money no matter how elegant the term sheet.

  • [ ] Commercial relevance. Does the patent cover something the market actually wants to build? The examiner asked only whether the claimed invention was new and non-obvious; the market asks the different and harder question of whether anyone will pay to use it. A patent on a technically brilliant dead end is worth nothing to a licensee.
  • [ ] Claim scope, read like a skeptic. Read the claims, not the glossy specification. Claims are the metes and bounds of the right to exclude; the specification is marketing. A broad independent claim that captures a fundamental way of solving the problem is worth many times a narrow claim a competitor sidesteps with a trivial redesign. For MarineFlow, the question is whether claim 1 covers "any elastomeric seat with a fluorinated coating" or only "a seat coated with compound X applied at temperature Y."
  • [ ] Validity strength. A patent likely to survive an inter partes review or a district-court invalidity attack commands a premium; a clean prosecution history with no buried prior-art problems is itself an asset you can charge for. Software and business-method patents carry an extra layer of eligibility risk under Alice; see Protecting Software and Business-Method Inventions After Alice.
  • [ ] Remaining term and maintenance status. Confirm the expiration date and that maintenance fees are current through USPTO Patent Center. A royalty stream cannot legally outlive the patent that supports it; a patent with three years left is a fundamentally different deal from one with fourteen. This constraint is not negotiable, and it drives the Brulotte/Kimble structuring in Phase 6.
  • [ ] Clean chain of title. Confirm you actually own what you propose to license. Broken assignment chains, an inventor who never signed over rights, or a co-inventor with an undivided interest can all sink a deal. Each joint owner may independently license the whole patent absent an agreement to the contrary, so an unaccounted-for co-owner is a competitor waiting to happen. Fix title with present-tense assignments before you sign; the mechanics are in Employee Invention Assignment Agreements: Securing Clean Title Across Jurisdictions.
  • [ ] Existing encumbrances. Is the patent already licensed to someone else, pledged as collateral, subject to a covenant not to sue, or burdened by a prior most-favored-licensee promise? Any of these narrows what you can grant. And screen early for the two big statutory overlays: Bayh-Dole obligations if the invention was federally funded (Phase 7), and FRAND commitments if the patent is essential to a technical standard.

The threshold in one sentence. You are deciding whether the patent is a revenue asset or a wall decoration, and the honest answer sometimes is that the best "license" is a defensive one, or none at all. If the patent is strong and the market real, proceed. If it is weak, consider whether litigation posture, a small non-exclusive program, or a sale makes more sense than a headline exclusive license you cannot support.

Phase 2 — Value the patent: walk in with a defensible range, not a magic number

Valuation is where most first-time licensors either leave money on the table or price the deal into oblivion. The professional move is to triangulate three independent methods into a defensible band, then negotiate inside it.

  • [ ] Cost approach. What would it cost Poseidon to design around the claims or independently develop an equally good valve seat? That figure sets a rational ceiling: a licensee will not pay more to license than to avoid. The cost approach is a floor-and-ceiling sanity check, not a precise value.
  • [ ] Market approach. Compare genuinely comparable licenses, adjusting for scope, exclusivity, field, territory, and term. Comparables are powerful but dangerous: the Federal Circuit has repeatedly excluded royalty testimony built on licenses that were not economically or technologically comparable to the patent in suit. See ResQNet.com, Inc. v. Lansa, Inc., 594 F.3d 860, 869-73 (Fed. Cir. 2010) (rejecting reliance on licenses with "no discernible link" to the claimed technology). Use royalty-rate databases and Licensing Executives Society survey data as a starting range, not as gospel.
  • [ ] Income approach. Model the incremental profit Poseidon earns because it has the patented seat rather than the next-best non-infringing alternative. This "but-for" premium is the economic heart of any royalty and the analytical core of the reasonable-royalty inquiry.
  • [ ] Georgia-Pacific as a negotiation checklist. The fifteen factors a court uses to construct a hypothetical negotiation are the same factors that set a fair rate across a real table. Georgia-Pacific Corp. v. U.S. Plywood Corp., 318 F. Supp. 1116, 1120 (S.D.N.Y. 1970). Walk through them deliberately: established rates, the licensee's anticipated profit, the relationship of the parties, the portion of profit attributable to the invention, the availability of substitutes.
  • [ ] Apportion the base, do not just pick a rate. Damages law requires separating the value of the patented feature from the value of everything else in the product. LaserDynamics, Inc. v. Quanta Computer, Inc., 694 F.3d 51, 67-68 (Fed. Cir. 2012); Finjan, Inc. v. Blue Coat Sys., Inc., 879 F.3d 1299, 1310 (Fed. Cir. 2018). Royalty on the whole product is available only under the narrow entire market value rule, which applies where the patented feature drives consumer demand for the entire product. Otherwise the base should approach the smallest salable patent-practicing unit. Some approximation is tolerated; VirnetX, Inc. v. Cisco Sys., Inc., 767 F.3d 1308, 1328 (Fed. Cir. 2014).
  • [ ] Treat the 25% "rule" as dead. The old rule of thumb, that a licensor should get roughly a quarter of the licensee's expected profit, survives only as a back-of-the-envelope gut check. The Federal Circuit held it inadmissible as evidence in Uniloc USA, Inc. v. Microsoft Corp., 632 F.3d 1292, 1315 (Fed. Cir. 2011), because it bore no relation to the specific facts of the case. Robert Goldscheider's original 25% rule is a heuristic, not a valuation.
  • [ ] Reduce the range to a one-page memo. Write down the band and the reasoning behind it. When Poseidon's counsel pushes back on the rate, you want a documented basis, not a number you cannot defend.

Two structural points that valuation newcomers miss. First, the reasonable-royalty framework that governs litigation damages is not academic to a transaction: it is the exact language a court will use to value the deal if the license ever falls apart, so the smartest licensor negotiates against that yardstick from the start. For the full damages architecture, see What an IP Case Is Worth: A Guide to Intellectual Property Damages. Second, exclusivity is itself a valuation input, not a separate topic: an exclusive license extinguishes competition and therefore commands a materially higher rate than a non-exclusive one, which is where Phase 3 begins.

Phase 3 — Define the grant: the single most important part of the deal

The grant clause is the DNA of the license. Everything else, the royalties and the machinery, is downstream of what rights you actually convey. Draft it with an engineer's precision.

  • [ ] Exclusivity: exclusive, sole, or non-exclusive. Choose deliberately and price accordingly.
  • [ ] Field of use. Restrict the grant to defined technical or commercial fields so you can license other fields to others.
  • [ ] Territory. Define the geographic scope, and align it with where the patent family actually exists.
  • [ ] Licensed patents. List patents, pending applications, continuations, and foreign counterparts by number, and decide the fate of future improvements explicitly.
  • [ ] Have-made rights. State whether the licensee may have licensed products manufactured by third parties on its behalf.
  • [ ] Sublicensing. State whether sublicenses are permitted, on what terms, and how sublicense revenue is shared.
  • [ ] Reserved rights. Reserve anything the licensor keeps: the right to practice, to license for research, to make defensive grants.

Exclusivity is the biggest price lever you own

An exclusive license removes every competitor, including, unless carefully reserved, the licensor itself, from the licensed field and territory. It commands a premium precisely because it is expensive to grant: you are giving up the ability to monetize the same patent again in that space. An exclusive licensee that holds "all substantial rights" may even acquire standing to sue infringers in its own name, an important power and a reason to define exactly which rights transfer. A sole license means the licensor and one licensee may both practice, but no one else. A non-exclusive license, by contrast, lets a licensor monetize one patent many times over; each licensee pays less, but the aggregate can dwarf a single exclusive deal, and non-exclusivity is the natural structure for standard-essential and widely useful technologies.

The exclusive/non-exclusive choice drives obligations, not just price. Grant exclusivity and you must protect against the partner who takes the field and then sits on it: attach diligence milestones, minimum annual royalties, and a right to convert to non-exclusive or terminate if the licensee fails to commercialize (Phase 4). Grant non-exclusivity and you take on the administrative burden of policing many licensees and, often, most-favored-licensee promises.

Field of use: slicing one patent into several revenue streams

Field-of-use restrictions are the licensor's scalpel. MarineFlow can license the valve seat to Poseidon for marine pumps, to a second company for oil-and-gas pipeline service, and to a third for municipal water systems, collecting from all three. Field-of-use limitations in patent licenses are lawful and long-blessed: the Supreme Court upheld them in General Talking Pictures Corp. v. Western Electric Co., 304 U.S. 175 (1938), where a licensee restricted to the home-radio field infringed by selling into the commercial-theater field. The doctrine is powerful but demands precision. Draw the field boundaries with an engineer's exactness, because a vague field definition is litigated years later as either a loophole the licensee exploits or an overreach that shades into misuse. "Marine applications" is a lawsuit; "pumps rated for continuous immersion in saltwater at depths of 0 to 300 meters" is a boundary.

Improvements and grant-backs: decide the future deliberately

Who owns tomorrow's better valve seat? If MarineFlow keeps inventing, its improvements may be exactly what makes the license valuable in year three, so Poseidon will want them included. Conversely, Poseidon's engineers will make their own refinements, and MarineFlow may want a grant-back license to those. Handle both explicitly and narrowly. An unbounded grant-back, one that sweeps in all of the licensee's future improvements on an exclusive, royalty-free, assign-back basis, is both commercially unfair and a potential patent-misuse and antitrust problem, because it can extend the licensor's market power beyond the licensed patent. The Department of Justice and FTC Antitrust Guidelines for the Licensing of Intellectual Property (2017) treat grant-backs under the rule of reason, weighing their tendency to reduce the licensee's incentive to innovate against their procompetitive sharing of risk. Keep grant-backs non-exclusive and reciprocal, and cabin them to improvements on the licensed claims.

Have-made rights, sublicensing, and reserved rights

A have-made right lets Poseidon outsource manufacture of the licensed valve to a contract foundry without that foundry needing its own license, so long as the products are made for Poseidon's account. Say so expressly; a bare license to "make, use, and sell" is often read not to include have-made rights, and a licensee that quietly outsources without them is infringing. Sublicensing is a separate right that must be granted explicitly, with its own economics: if Poseidon may sublicense into adjacent markets, define the royalty split (a common structure is a percentage of sublicense income) and require that sublicensees be bound by the material terms, including reporting and audit. Finally, reserve what you keep in writing. If MarineFlow wants to keep practicing the invention for its own research, or to grant defensive non-exclusive licenses to settle future disputes, an exclusive grant that fails to reserve those rights silently surrenders them.

For the parallel grant-clause analysis in the software world, where the covenant-versus-condition line and scope limits work much the same way, compare Software License Agreements: Key Terms and How to Negotiate Them.

Phase 4 — Design the royalty architecture

Royalty design is where a well-drafted grant becomes money. The goal is a structure that pays the licensor fairly, survives an audit, and does not trip a doctrinal wire.

  • [ ] Upfront / lump sum. A signing payment that de-risks the deal and signals the licensee's commitment.
  • [ ] Running royalty: rate and base. Fix both the percentage and, more importantly, the base it multiplies, apportioned to the patented feature.
  • [ ] Minimum annual royalties and milestones. Protect against the exclusive licensee who shelves the invention.
  • [ ] Most-favored-licensee (MFL) terms. Consider whether, and how, to promise no worse terms than later licensees get.
  • [ ] Net sales definition. Pin down, with no ambiguity, what "net sales" means and which deductions are allowed.
  • [ ] Reporting, currency, interest, and late payment. Set frequency, currency, and the consequences of a short payment.
  • [ ] Keep every royalty inside the patent term (or structure around it; see Phase 6).

Upfronts, running royalties, and the base problem

An upfront payment shifts risk from licensor to licensee and is standard in exclusive deals; it also anchors the licensor's return if the product underperforms. A running royalty ties the licensor's return to the licensee's success, which aligns incentives but exposes the licensor to the licensee's execution risk. The single most litigated element is not the rate but the base. A 5% royalty means nothing until you define 5% of what. Royalty on the entire finished pump when the patent covers only the valve seat is the apportionment error courts police in litigation (Phase 2), and the same logic should discipline the transaction. Convenience cuts the other way, though: the Supreme Court has held that parties may lawfully agree, for administrative ease, to compute royalties on total sales of a product line even where not every unit practices the patent, so long as that base is a negotiated convenience rather than a coerced condition. Automatic Radio Mfg. Co. v. Hazeltine Research, Inc., 339 U.S. 827 (1950). But if the licensor requires royalties on unpatented products as a condition of the license, that crosses into misuse. Zenith Radio Corp. v. Hazeltine Research, Inc., 395 U.S. 100, 135-40 (1969). The safe path: apportion honestly, and if you use a broad base, make the record show the licensee proposed or accepted it for convenience.

Minimums, milestones, and the anti-shelving problem

The nightmare of an exclusive license is the partner who takes the field, then does nothing, leaving the licensor with no royalties and no ability to license anyone else. Minimum annual royalties and diligence milestones are the cure. Structure them as escalating minimums (say, a floor that steps up each year) plus objective commercialization milestones (first commercial sale by a date certain, regulatory clearance where relevant), with a right to convert the exclusive grant to non-exclusive, or to terminate, on a missed milestone. For MarineFlow, a term sheet that grants Poseidon exclusivity but requires a first commercial sale within eighteen months and a minimum royalty of a stated dollar figure per year keeps Poseidon honest and MarineFlow solvent.

Most-favored-licensee clauses and net sales

A most-favored-licensee clause promises a licensee that if the licensor later grants anyone better terms, this licensee gets them too. Licensees love MFL clauses; licensors should grant them sparingly, because they are administratively expensive (every future deal must be compared) and they cap upside. If you grant one, define the comparison precisely: is it rate-by-rate, or a "no better overall package" test that lets you weigh a lower rate against a higher upfront? The net sales definition is the other quiet battleground. Deductions, returns, freight, insurance, taxes, discounts, can shrink the base dramatically, and each is negotiated. Define net sales as a closed list, cap total deductions as a percentage, and address affiliate and non-arm's-length sales (royalties should compute on a deemed arm's-length price to prevent transfer-pricing games).

Know-how and the hybrid royalty

Patents rarely travel alone. The valve seat is worthless to Poseidon without MarineFlow's manufacturing know-how, the trade-secret process for applying the coating. A hybrid patent-and-know-how license bundles both, and it lets a licensor keep collecting after the patent expires, because trade-secret and know-how royalties are not bound by the patent term. But the structure must be drafted with care: bundle patent and non-patent royalties inseparably at a single undifferentiated rate that runs past patent expiration, and a court may hold the whole obligation unenforceable beyond the last patent's expiry. See Phase 6; Pitney Bowes, Inc. v. Mestre, 701 F.2d 1365 (11th Cir. 1983). The fix is to state separate, separately justified royalties for the patent rights and the know-how, and to step the patent portion down to zero at expiration while the know-how portion (if genuinely independent) continues. For the underlying trade-secret discipline that makes a know-how royalty defensible, see Building Trade Secret Protection from the Ground Up and the layered strategy in How the Law Protects Software.

Phase 5 — Build the protective machinery

The grant and the royalty make the deal; the protective machinery keeps it alive. These clauses are where licensors most often under-invest, and where the money leaks.

  • [ ] Audit rights. The right to inspect the licensee's books on notice, with cost-shifting if an audit finds an underpayment over a threshold (commonly 5%).
  • [ ] Representations and warranties. Ownership, authority to grant, and, carefully scoped, non-infringement, with express disclaimers of anything broader.
  • [ ] Indemnification. Who bears third-party infringement and product-liability claims, and subject to what caps.
  • [ ] Prosecution and maintenance. Who pays maintenance fees and controls prosecution of pending applications and continuations.
  • [ ] Enforcement. Who has the right and the duty to sue infringers, who controls the litigation, and how recoveries are split.
  • [ ] Marking. Require the licensee to mark licensed products under 35 U.S.C. § 287.
  • [ ] Term, termination, survival, and bankruptcy. Termination for breach, insolvency, and challenge; which obligations survive; and protection if a party files bankruptcy.

Audit rights are self-funding if you draft them right

A running-royalty licensor is trusting the licensee's own accounting. Audit rights make that trust verifiable. Grant the licensor (or its independent accountant) the right to inspect relevant records once per year on reasonable notice, and add a cost-shifting trigger: if the audit finds an underpayment exceeding a threshold, the licensee pays for the audit plus interest on the shortfall. Without the trigger, audits cost the licensor money to run and are rarely worth it; with it, they pay for themselves and deter creative accounting. Cap the look-back period (three years is typical) and require records to be kept that long.

Representations, warranties, and the non-infringement trap

A licensor should represent that it owns the licensed patents and has authority to grant the license. It should think hard before warranting non-infringement or validity. A licensor does not control whether a third party's patent dominates the field, and a broad non-infringement warranty converts the licensor into an insurer of the licensee's entire freedom to operate. Scope any such warranty narrowly (for example, "to the licensor's knowledge, without duty of investigation, the licensed patents are not infringed by no products other than..."), and disclaim implied warranties of merchantability and fitness. The licensee will push for more; the negotiation is really about who bears the risk that someone else owns a blocking patent, which the licensee can and should investigate through its own freedom-to-operate analysis. See Clearing a Product for Launch: How to Conduct a Freedom-to-Operate Analysis and the workflow in Running a Freedom-to-Operate Patent Search: A Practical Checklist.

Prosecution, maintenance, enforcement, and marking

Someone must pay the patent's maintenance fees, or the asset dies mid-license; say who, and give the paying party audit rights over the timely payment. Decide who controls prosecution of pending applications and continuations, since claim amendments during the license can expand or shrink what the licensee bought. Enforcement is a right and often a duty: an exclusive licensee usually wants the right to sue infringers (and standing to do so requires the grant of all substantial rights), while the licensor wants a backstop right to sue if the licensee declines, plus a formula for splitting recoveries. Marking is not optional housekeeping. Under 35 U.S.C. § 287, a patentee (and its licensees) that sells unmarked products cannot recover damages for the period before actual notice to the infringer, and a single unmarked licensee product can destroy the patentee's constructive notice for everyone. Require the licensee to mark, police compliance, and permit virtual marking. The mechanics are in Patent Marking Requirements: A Practical Guide and the operational steps in Patent Marking and Constructive Notice: A Practical Checklist.

Term, termination, survival, and the bankruptcy backstop

State the term (typically the life of the last-to-expire licensed patent, or a fixed period, whichever aligns with the royalty structure). Define termination rights for uncured material breach, for insolvency, and, carefully, for a validity challenge (Phase 6). Specify survival: which obligations (confidentiality, accrued royalties, audit of the final period, indemnity for pre-termination acts) outlast the agreement. And address bankruptcy. If the licensor files, a licensee's rights are protected by 11 U.S.C. § 365(n), enacted to reverse Lubrizol Enterprises, Inc. v. Richmond Metal Finishers, Inc., 756 F.2d 1043 (4th Cir. 1985), which had let a bankrupt licensor strip a licensee of its patent rights. Section 365(n) lets the licensee elect to retain its license despite rejection, a protection every exclusive licensee should invoke expressly in the agreement. For the breach-remedy backdrop when a license is treated as an ordinary contract, see Contract Damages: How Courts Make the Injured Party Whole.

Phase 6 — The silent doctrinal landmines

Here is what separates a competent term sheet from a dangerous one. Four doctrines can quietly void a royalty stream a licensor believed was airtight, and none of them announces itself until a dispute. Pressure-test every term sheet against all four before signing.

  • [ ] No post-expiration royalties (Brulotte / Kimble).
  • [ ] The licensee's inalienable right to challenge validity (Lear / MedImmune).
  • [ ] Exhaustion after the first authorized sale (Quanta / Impression Products).
  • [ ] Patent misuse and antitrust (Morton Salt / Illinois Tool Works / Zenith).

Landmine 1: royalties may not outlive the patent (Brulotte and Kimble)

A licensor may not collect royalties for the use of an invention after the patent expires. The Supreme Court so held in Brulotte v. Thys Co., 379 U.S. 29 (1964), striking down a hop-picking-machine license whose royalties ran past the patents' expiration. Fifty years later, in Kimble v. Marvel Entertainment, LLC, 576 U.S. 446 (2015), the Court reaffirmed Brulotte under stare decisis, refusing to overrule it even as it conceded the economic criticism. Kimble had licensed a Spider-Man web-shooter toy patent to Marvel for a running royalty with no end date; when the patent expired, so did Marvel's obligation to pay. The rule is formalistic and unforgiving: a deal that ties a single undifferentiated royalty to a basket of patents and keeps paying the same rate after the last one expires is unenforceable as to the post-expiration period.

The doctrine is a drafting problem, not a barrier, because Kimble itself catalogued the lawful workarounds. Step-downs: reduce the royalty as patents in the portfolio expire, to zero at the last expiration. Amortization: structure a fixed total payment over a period that may extend past expiration, so long as the amount reflects pre-expiration use rather than post-expiration use (deferring payment for pre-expiration use is fine; charging for post-expiration use is not). Genuinely separate non-patent royalties: charge a distinct, independently justified royalty for trade secrets, know-how, or services that can lawfully continue after the patent dies, as Aronson v. Quick Point Pencil Co., 440 U.S. 257 (1979), confirmed when it enforced a reduced ongoing royalty for an unpatented design where the parties had knowingly priced the risk that no patent would issue. For MarineFlow, the clean structure is a patent royalty that steps to zero at the patent's 2039 expiration and a separate, lower know-how royalty for the coating process that continues only so long as the process remains secret and useful. The hybrid drafting discipline is exacting; get it wrong and the whole obligation can collapse past expiration.

Landmine 2: you cannot stop a licensee from challenging the patent (Lear and MedImmune)

A licensee cannot be contractually barred from challenging the validity of the very patent it licenses. In Lear, Inc. v. Adkins, 395 U.S. 653 (1969), the Supreme Court abolished the old doctrine of licensee estoppel, reasoning that the public interest in purging invalid patents outweighs the licensor's contractual expectation, because licensees are often the only parties with both the knowledge and the economic incentive to test a shaky patent. MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007), went further: a licensee in good standing may sue for a declaratory judgment of invalidity without first breaching the license or stopping its royalty payments, so it can attack the patent while continuing to pay under protest.

The consequence: a naked no-challenge clause is worth nothing. But the term sheet has enforceable substitutes. A challenge-triggered royalty escalation (the rate jumps if the licensee sues) makes a validity challenge expensive without forbidding it. A termination-on-challenge clause lets the licensor cancel the license, and its favorable rate, if the licensee attacks, which post-Lear authority has generally tolerated because it does not bar the challenge, it merely ends the deal. A fee-shifting provision requiring the losing challenger to bear litigation costs adds friction. Note that a no-challenge clause embedded in a settlement of actual litigation stands on firmer ground than one in an ordinary license, because there the public interest in resolving disputes counterweighs Lear. Draft for deterrence, not prohibition.

Landmine 3: the first authorized sale exhausts your control (Quanta and Impression Products)

Once a patentee authorizes the sale of a patented article, its patent rights in that particular article are exhausted; it cannot use patent law to control what the buyer does downstream. The Supreme Court applied the doctrine to method patents and component sales in Quanta Computer, Inc. v. LG Electronics, Inc., 553 U.S. 617 (2008), holding that an authorized sale of chips that substantially embodied the patented methods exhausted LG's rights against downstream computer makers. Then, in Impression Products, Inc. v. Lexmark International, Inc., 581 U.S. 360 (2017), the Court swept away the Federal Circuit's contrary rule from Mallinckrodt, Inc. v. Medipart, Inc., 976 F.2d 700 (Fed. Cir. 1992), and held two things that reshaped licensing: (1) a patentee's sale exhausts its patent rights even when the patentee tries to impose a clearly worded post-sale restriction, so a "single use only" label on a sold cartridge is a matter of contract, not patent infringement; and (2) an authorized sale anywhere in the world, including abroad, exhausts U.S. patent rights, ending the practice of price-discriminating across borders through patent law.

For the term sheet, exhaustion means you cannot use the patent grant to reach conduct downstream of an authorized sale. If MarineFlow wants Poseidon's customers to buy replacement seats only from Poseidon, patent law will not deliver that after the pump is sold; the licensor must rely on contract, and contract binds only parties in privity. This is the doctrinal engine behind the modern right-to-repair debates; see The Right to Repair Reckoning: IP Limits on Post-Sale Product Control. Structure downstream expectations as covenants running to the licensee and its direct customers, and price the license understanding that a sold unit is a free unit as far as the patent is concerned.

Landmine 4: misuse and antitrust can unenforce the patent against the world

Patent misuse is the doctrine that a patentee who leverages its patent beyond the lawful scope of the grant renders the patent unenforceable, against everyone, until the misuse is purged. It originates in Morton Salt Co. v. G.S. Suppiger Co., 314 U.S. 488 (1942), where a patentee conditioned its salt-tablet-machine license on buying its unpatented salt tablets and lost the ability to enforce the patent at all. That is a far worse outcome than a merely unfavorable license: misuse can vaporize the entire asset. The classic misuse triggers are tying (conditioning the patent license on the purchase of a separate unpatented product or a license to a second patent), coerced package licensing and royalties on unpatented products (Zenith, above), overbroad field or territorial restraints that exceed the patent's scope, and improper post-expiration royalties (which is Brulotte wearing a misuse hat).

Modern law has narrowed misuse in two important ways. First, Congress amended 35 U.S.C. § 271(d) so that a patentee no longer commits misuse merely by tying or refusing to license absent market power, and the Supreme Court reinforced this in Illinois Tool Works Inc. v. Independent Ink, Inc., 547 U.S. 28 (2006), holding that a patent no longer creates a presumption of market power in a tying case; the plaintiff must prove it. Second, the Federal Circuit, sitting en banc in Princo Corp. v. International Trade Commission, 616 F.3d 1318 (Fed. Cir. 2010), confined misuse to conduct that actually broadens the physical or temporal scope of the patent with anticompetitive effect. Most licensing restraints are now judged under the antitrust rule of reason, weighing anticompetitive harm against procompetitive justification, as the DOJ/FTC Antitrust Guidelines for the Licensing of Intellectual Property (2017) reflect. Only a short list of practices, naked price-fixing, market division among horizontal competitors, and output restraints, remains per se unlawful. The practical takeaway for the term sheet: legitimate field-of-use, territorial, and quantity limits are fine; conditioning the license on unrelated purchases, coercing a package, or restraining the licensee's dealings in unpatented goods is not. When in doubt, ask whether the restraint protects the value of this patent or reaches for market power beyond it.

For a tour of how these doctrines have played out in real disputes, see Landmark Patent Wars: Strategic Lessons From High-Profile Case Studies, and for the enforcement backdrop, Litigating Patent Infringement: A Roadmap and Research Guide.

Phase 7 — Tailor the term sheet to special licensors

Some patents come with statutory strings that constrain the grant no matter what the parties want. Screen for these in Phase 1 and account for them here.

  • [ ] University / federally funded (Bayh-Dole). Confirm whether the invention was made with federal funding, and build in the government's reserved rights.
  • [ ] Standard-essential patents (FRAND). If the patent is essential to a technical standard, honor the FRAND commitment.
  • [ ] Government contractor and export overlays. Check for government march-in, U.S.-manufacture, and export-control constraints.

University and Bayh-Dole licenses

Inventions made with federal funding are governed by the Bayh-Dole Act, 35 U.S.C. §§ 200-212, and its regulations at 37 C.F.R. Part 401. A university or nonprofit that elects to retain title to a funded invention takes it subject to statutory conditions that flow through to any license: the government keeps a nonexclusive, nontransferable, paid-up license to practice the invention worldwide; the government retains march-in rights to compel licensing in defined circumstances (nonuse, health or safety needs); and products embodying the invention that are sold in the United States must be substantially manufactured in the United States, subject to waiver on a showing that domestic manufacture is not commercially feasible. A university licensor also typically reserves the right to practice and to license the invention for its own research and educational purposes, and must keep the license consistent with its public-benefit mission, which is why university term sheets are negotiated through technology-transfer offices and rarely surrender the reserved research right. Note too that Bayh-Dole does not automatically vest title in anyone: as the Supreme Court held in Board of Trustees of Leland Stanford Junior University v. Roche Molecular Systems, Inc., 563 U.S. 776 (2011), the inventor still owns the invention absent an effective assignment, so clean chain of title (Phase 1) matters even more in the university setting. A Poseidon-style licensee taking from a university should expect these terms as non-negotiable overlays, not as opening positions.

Standard-essential patents and FRAND

If MarineFlow's patent were instead essential to an industry standard, everything changes. Standards-development organizations require members to disclose essential patents and to commit to license them on fair, reasonable, and non-discriminatory (FRAND) terms, precisely to prevent holdup, the danger that a patent owner, once the industry is locked into a standard, extracts royalties far above the patent's true technological value by threatening to enjoin standard-compliant products. A FRAND commitment reshapes the term sheet in three ways. First, the licensor generally cannot refuse to deal or demand exclusivity; it must license all comers. Second, the royalty base is contested and often driven toward the smallest salable patent-practicing unit rather than the end product, an argument litigated in the Ericsson v. D-Link line, 773 F.3d 1201 (Fed. Cir. 2014), and in the handset FRAND disputes. Third, the availability of an injunction is constrained: after eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388 (2006), injunctions are discretionary, and courts are especially reluctant to enjoin standard-compliant products where the patentee has promised to license. Global rate-setting has become its own battleground, from the Federal Circuit's treatment of court-set FRAND rates in TCL Communication v. Ericsson, 943 F.3d 1360 (Fed. Cir. 2019), to the U.K. Supreme Court's willingness to set a worldwide rate in Unwired Planet v. Huawei (2020). For the full treatment, see Standard-Essential Patents and FRAND Licensing in the 5G and IoT Era, and for the cross-border enforcement dimension, Cross-Border Patent Litigation.

Phase 8 — From term sheet to signed license, and closing mechanics

The term sheet is the blueprint; now build the house and record the deed.

  • [ ] Definitive agreement. Translate the term sheet into a complete license, resolving every "to be negotiated" item, and confirm that each signatory has corporate authority to bind.
  • [ ] Governing law, forum, and dispute resolution. Pick governing law and a dispute-resolution mechanism deliberately.
  • [ ] Recording. Record the assignment or exclusive license with the USPTO where appropriate.
  • [ ] Calendar every deadline. Docket royalty reports, minimum-payment dates, audit windows, milestone deadlines, and maintenance-fee due dates.

Definitive agreement. The move from term sheet to license is where the deferred decisions come due: the exact net-sales definition, the audit mechanics, the indemnity caps, the survival schedule. Confirm signatory authority on both sides; a license signed by someone without corporate power to bind is a dispute waiting to happen.

Dispute resolution and governing law. Patent licenses generate two very different kinds of disputes, contract disputes (did the licensee underpay?) and patent disputes (is the patent valid and infringed?), and a single forum clause governs both. Arbitration keeps royalty disputes confidential and fast but can be an awkward fit for validity questions, though 35 U.S.C. § 294 expressly makes patent validity and infringement arbitrable between the parties (the award binds only them). Choose deliberately; the trade-offs are laid out in Choosing a Dispute-Resolution Forum: Litigation, Arbitration, and Mediation Compared.

Recording. Under 35 U.S.C. § 261, an assignment or exclusive license is void against a subsequent bona fide purchaser for value unless recorded with the USPTO within the statutory window (three months from the transaction, or before the later purchase). Recording an exclusive license protects the licensee's priority against later grantees. Non-exclusive licenses are generally not recorded.

Calendar everything. The most common way a good license leaks value is administrative: a missed maintenance fee that lets the patent lapse, an unmonitored minimum-royalty date, an audit right that goes stale. Build the calendar the day you sign.

A one-page term-sheet skeleton (worked example)

Here is the MarineFlow-Poseidon term sheet reduced to its load-bearing lines, the shape a clean patent license term sheet takes on the page (hypothetical, illustrative only):

  • Parties. MarineFlow, Inc. (Licensor); Poseidon Pumps, LLC (Licensee).
  • Licensed patents. U.S. Patent No. 9,XXX,XXX and its continuations, divisionals, and foreign counterparts listed in Schedule A.
  • Grant. Exclusive, non-transferable license to make, use, have made, and sell Licensed Products, with have-made rights, in the Field (pumps and valves rated for continuous saltwater immersion, 0-300 m) and Territory (worldwide).
  • Reserved rights. Licensor retains the right to practice for internal research and to grant non-exclusive licenses outside the Field.
  • Sublicensing. Permitted into adjacent marine sub-fields with Licensor's consent; 25% of sublicense income payable to Licensor.
  • Upfront. $[ ] on signing, non-refundable, non-creditable against royalties.
  • Running royalty. [ ]% of Net Sales of Licensed Products, apportioned to the valve-seat unit; Net Sales defined in Schedule B with capped deductions.
  • Minimums / diligence. Minimum annual royalty of $[ ]; first commercial sale within 18 months; conversion to non-exclusive on a missed milestone.
  • Know-how. Separate [ ]% royalty for the coating process trade secrets, continuing only while the process remains secret and useful; patent royalty steps to zero at patent expiration (Brulotte/Kimble compliance).
  • Audit. Annual inspection; Licensee pays audit cost plus interest on any underpayment exceeding 5%.
  • Reps/warranties. Ownership and authority to grant; non-infringement limited to Licensor's knowledge; implied warranties disclaimed.
  • Indemnity. Mutual, capped at [ ]x fees paid in the trailing 12 months, with a carve-out for third-party IP claims.
  • Enforcement. Licensee has first right to sue in the Field; Licensor backstop; recoveries split after costs.
  • Marking. Licensee to mark under § 287; virtual marking permitted; compliance policed.
  • Term/termination. Life of last-to-expire licensed patent; termination for uncured breach, insolvency (subject to § 365(n)), and challenge (royalty escalates on validity challenge).
  • Boilerplate. Governing law; dispute resolution; recording of the exclusive license under § 261; confidentiality (binding on signature); non-binding as to the balance pending a definitive agreement.

That skeleton is not a contract; it is the discipline that produces one. Every line traces back to a phase above, and every phase traces back to a doctrine.

Common mistakes that quietly cost licensors money

  • Pricing off a single number instead of a documented range. When the licensee pushes, you have nothing to stand on.
  • Setting a rate but not defining the base. Apportionment is half the deal; an undefined base is an unlimited discount.
  • A naked no-challenge clause. Unenforceable under Lear; use a challenge-triggered royalty bump and termination-on-challenge instead.
  • A royalty tail past expiration. Uncollectible under Brulotte/Kimble; step the patent royalty down and separate any know-how royalty.
  • An exclusive grant with no minimums or diligence. A partner who shelves your invention and blocks everyone else.
  • Forgetting licensee marking obligations. One unmarked licensee product can erase pre-notice damages under § 287.
  • Trying to control conduct after an authorized sale. Exhaustion ended that; use contract, and remember contract needs privity.
  • Overreaching restraints. Tying and coerced packages risk misuse that can unenforce the whole patent.
  • Ignoring statutory overlays. Bayh-Dole and FRAND rewrite the grant whether or not the parties acknowledge them.

How this fits the larger transaction

A term sheet is one instrument in a portfolio of decisions. Upstream, the strength of the patent you are licensing was determined by how well the invention was captured; see Drafting an Invention Disclosure That Maximizes Patent Scope and, for the mechanics, Drafting an Invention Disclosure: A Practical Checklist. The right to exclude you are monetizing is defined by the infringement framework in What Counts as Patent Infringement: An Anatomy of the Section 271 Analysis and Patent Infringement, Claims, and Defenses. And the whole enterprise sits inside the U.S. patent system mapped in The U.S. Patent System: An Overview and the granular How U.S. Patents Work: A Comprehensive Practical Guide. A patent license is finally just the most valuable species of contract a technology company signs; treat the term sheet with the seriousness that value deserves.

Primary authority

This checklist is educational and does not constitute legal advice. Patent licensing decisions turn on specific facts, the exact claim language, and current law. Consult qualified patent counsel before signing any license or term sheet.

Related UpLaw Resources

Related Guides

Related Checklists

Related Toolkits

Related Articles